

Supplementary Table S1.

Patients eligible for MRD study (CR1 after 3+7 regimen)	75
Post-remission therapy	
Chemotherapy alone	54
ATSP	10
Allo-TMO	11
MRD controls	
MRD-MFC post cycle 1	75
MRD-MFC and qPCR post cycle 1	42
Successive MRD-MFC and qPCR monitoring	161
MRD-MFC and qPCR post cycle 2	39
MRD-MFC and qPCR post cycle 3 or +	69
Patients non eligible for MRD study	70
Induction Chemotherapy	
3+7 regimen (no CR)	22
ATRA based regimens (acute promyelocytic leukemia)	11
5-azacytidine based regimens	15
Other treatments	9
Palliative care	9
Early deaths	4
Post-remission therapy	
Chemotherapy	21
ATSP	5
Allo-TMO	6

Supplementary Table S2.

	Specificity mean (range)	<0.01%	≥0.01-0.1%	>0.1
T1	0,0845 (0,0002636- 1,24165)	28 (32%)	43 (49%)	16 (18%)
T2	0,1035 (0,0009616- 2,6067938)	17 (16%)	49 (46%)	34 (32%)
T3	0,0843 (0,00020497- 3,547254)	43 (42%)	43 (42%)	15 (15%)
T4	0,1104 (0,000247- 2,54468)	27 (30%)	45 (50%)	18 (20%)
T5	0,0814 (0,0002615- 2,215884)	30 (30%)	48 (48%)	21 (21%)
T6	0,0481 (0,00066- 0,8041249)	39 (39%)	50 (50%)	11 (11%)

Number of different LAIPs detected in the 6 first combinations of the AML/MDS panel. LAIPs were classified in 3 categories of specificity: strong, good and weak (<0.01%, ≥0.01-0.1% and >0.1). General specificity (mean + range) of LAIPs in each single combination.

*T1-6: tube 1-6